Dorsey & Whitney Trust CO LLC Acquires 4,939 Shares of Pfizer Inc. (NYSE:PFE)

Dorsey & Whitney Trust CO LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 6.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 77,406 shares of the biopharmaceutical company’s stock after acquiring an additional 4,939 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Pfizer were worth $2,166,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PFE. Cantor Fitzgerald Investment Advisors L.P. acquired a new stake in Pfizer in the fourth quarter valued at approximately $16,166,000. LGT Group Foundation boosted its holdings in shares of Pfizer by 2.5% during the 2nd quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after acquiring an additional 18,274 shares in the last quarter. First Heartland Consultants Inc. grew its position in Pfizer by 43.3% during the 4th quarter. First Heartland Consultants Inc. now owns 13,013 shares of the biopharmaceutical company’s stock worth $375,000 after acquiring an additional 3,933 shares during the last quarter. ORG Partners LLC increased its holdings in Pfizer by 1,729.9% in the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock worth $1,327,000 after purchasing an additional 44,458 shares in the last quarter. Finally, Kempner Capital Management Inc. bought a new position in Pfizer in the first quarter valued at about $2,439,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock opened at $29.40 on Tuesday. The stock’s 50 day moving average price is $29.08 and its two-hundred day moving average price is $28.07. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $34.62. The stock has a market capitalization of $166.60 billion, a price-to-earnings ratio of -489.92, a PEG ratio of 1.00 and a beta of 0.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same period last year, the business posted $0.67 EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.71%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer’s payout ratio is -2,799.53%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on PFE shares. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Monday. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays increased their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, UBS Group lifted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.